17,510 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Purchased by Fox Run Management L.L.C.

Fox Run Management L.L.C. bought a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALOFree Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 17,510 shares of the biopharmaceutical company’s stock, valued at approximately $669,000.

Other hedge funds have also recently bought and sold shares of the company. US Bancorp DE increased its holdings in Halozyme Therapeutics by 43.8% during the 1st quarter. US Bancorp DE now owns 12,663 shares of the biopharmaceutical company’s stock worth $506,000 after purchasing an additional 3,859 shares during the period. HighTower Advisors LLC increased its holdings in shares of Halozyme Therapeutics by 7.3% in the 1st quarter. HighTower Advisors LLC now owns 11,952 shares of the biopharmaceutical company’s stock valued at $477,000 after acquiring an additional 812 shares during the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of Halozyme Therapeutics by 31.9% in the 1st quarter. PNC Financial Services Group Inc. now owns 16,826 shares of the biopharmaceutical company’s stock valued at $671,000 after acquiring an additional 4,066 shares during the last quarter. Natixis Advisors L.P. increased its holdings in shares of Halozyme Therapeutics by 14.9% in the 1st quarter. Natixis Advisors L.P. now owns 30,219 shares of the biopharmaceutical company’s stock valued at $1,205,000 after acquiring an additional 3,928 shares during the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its holdings in shares of Halozyme Therapeutics by 10.5% in the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 51,597 shares of the biopharmaceutical company’s stock valued at $2,058,000 after acquiring an additional 4,920 shares during the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on HALO. The Goldman Sachs Group dropped their price objective on Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating on the stock in a report on Thursday, January 18th. TheStreet downgraded Halozyme Therapeutics from a “b-” rating to a “c+” rating in a research note on Monday, January 22nd. Benchmark restated a “buy” rating and set a $50.00 price target on shares of Halozyme Therapeutics in a research note on Friday, January 19th. HC Wainwright dropped their price target on Halozyme Therapeutics from $61.00 to $48.00 and set a “buy” rating on the stock in a research note on Thursday, January 18th. Finally, Morgan Stanley dropped their price target on Halozyme Therapeutics from $61.00 to $59.00 and set an “overweight” rating on the stock in a research note on Tuesday, December 26th. Four equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $51.45.

Read Our Latest Stock Analysis on HALO

Insider Buying and Selling

In related news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $39.63, for a total transaction of $396,300.00. Following the completion of the transaction, the senior vice president now directly owns 151,911 shares of the company’s stock, valued at $6,020,232.93. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 2.30% of the stock is currently owned by insiders.

Halozyme Therapeutics Stock Down 1.9 %

HALO opened at $33.77 on Wednesday. The company has a debt-to-equity ratio of 6.01, a current ratio of 7.63 and a quick ratio of 6.51. The business has a 50 day simple moving average of $37.31 and a 200-day simple moving average of $38.80. The stock has a market capitalization of $4.46 billion, a P/E ratio of 17.96, a P/E/G ratio of 0.36 and a beta of 1.23. Halozyme Therapeutics, Inc. has a 12 month low of $29.85 and a 12 month high of $53.71.

Halozyme Therapeutics (NASDAQ:HALOGet Free Report) last posted its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported $0.69 EPS for the quarter, beating the consensus estimate of $0.67 by $0.02. The business had revenue of $216.03 million during the quarter, compared to analysts’ expectations of $219.47 million. Halozyme Therapeutics had a return on equity of 190.74% and a net margin of 32.52%. On average, equities analysts anticipate that Halozyme Therapeutics, Inc. will post 2.56 earnings per share for the current fiscal year.

Halozyme Therapeutics Company Profile

(Free Report)

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Featured Articles

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALOFree Report).

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.